Substance Abuse Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Substance Abuse Treatment Market is segmented by Treatment Type (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Drug Abuse Treatment, and Other Treatment Types), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

Market Snapshot

Substance Abuse Treatment Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.2 %
Substance Abuse Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The substance abuse treatment market is expected to register a CAGR of 7.2% during the forecast period.

Due to the COVID-19 pandemic, government authorities across the world have taken the necessary steps to make substance abuse treatment accessible to patients. This can be attributed to the fact that the prognosis of patients' co-occurring conditions, such as chronic obstructive pulmonary disease, cardiovascular disease, and other respiratory diseases, is worsened by COVID-19, negatively impacting the lives of substance-addicted and alcohol-addicted patients. For instance, an article titled "Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond," published in November 2021, stated that federal and state governments implemented temporary strategies for providing access to opioid use disorder (OUD) treatment during the COVID-19 pandemic. The article also stated that all the states and Washington, DC had adopted at least one telehealth policy in order to improve access to OUD treatment for new patients. Thus, there has been an increase in demand for substance abuse treatment amid the ongoing COVID-19 pandemic.

Further, the factors that are driving the market growth include rising drug awareness campaigns and prevention programs and growth in the number of addictions among the population. The surge in drug awareness campaigns and associated prevention programs is one of the primary factors linked to the growth of the market studied. This includes rising patient awareness, a higher treatment-seeking rate with increased government intervention, and encouragement to curb substance abuse in several countries. For instance, in December 2021, the Indian government launched the "Drug-Free India" campaign and issued directions for curbing drug abuse in the Indian populace. Likewise, in October 2021, the Centers for Disease Control and Prevention (CDC) launched four complementary education campaigns intended to reach young adults ages 18–34 years aimed at preventing drug overdose deaths. The campaigns provide information about the prevalence and dangers of fentanyl, the risks and consequences of mixing drugs, the life-saving power of naloxone, and the importance of reducing the stigma around drug use to support treatment and recovery. Such campaigns and initiatives are increasing awareness regarding substance abuse treatment among the addicted population, thereby contributing to the market's growth.

However, the reluctance of individuals to access treatment modalities, the discontinuation of behavioral therapies, and poor treatment compliance in some countries hinder the growth of the market studied.

Scope of the Report

As per the scope of the report, substance abuse refers to the abusive use of psychoactive substances, including illicit drugs, tobacco, and alcohol. Substance abuse treatment helps the patient rid the body of any drugs and alcohol that are left in the system and/or reduces drug cravings. The substance abuse treatment market is segmented by treatment type (alcohol addiction treatment, tobacco/nicotine addiction treatment, drug abuse treatment, and other treatment types), distribution channel (hospital pharmacies, retail pharmacies, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments.

By Treatment Type
Alcohol Addiction Treatment
Tobacco/Nicotine Addiction Treatment
Drug Abuse Treatment
Other Treatment Types
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Tobacco/Nicotine Addiction Treatment Segment is Expected to Dominate the Market

By treatment type, the tobacco/nicotine addiction treatment segment is anticipated to witness lucrative growth. Tobacco and its usage through consumption and smoking are harmful, as they kill half of its users globally, as stated by the World Health Organization. In July 2021, the same source stated that tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use, while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Moreover, the use of tobacco is greater in developing and underdeveloped countries, especially in the Pacific and East Asian countries. Such factors are anticipated to boost the growth of the segment in the developing as well as developed countries over the coming years.

Furthermore, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in December 2021, the NFL Biosciences launched the Phase II/III clinical trial to assess the efficacy and safety of its NFL-101 smoking cessation treatment. It is approved by the Human Research Ethics Committee (HREC) in Australia and by the French National Agency for the Safety of Medicines and Health Products (ANSM). Similarly, in September 2021, Mydecine Innovations Group launched a Phase 2/3 clinical trial for smoking cessation for its MYCO-001 compound, following up on its recent announcement of 5-year cooperation with Johns Hopkins University's research institute. In this ground-breaking trial, Mydecine will collaborate with John Hopkins, and the trial will be a randomized, double-blind, placebo-controlled experiment to assess the efficacy of Mydecine's MYCO-001 in the treatment of nicotine addiction.

Hence, all these factors are expected to help this market grow during the forecast period.

Total Hospital Admissions for Diseases Caused by Smoking, Adult Aged 35 Years and Over, United Kingdom (England), 2020

North America is Expected to Dominate the Market During the Forecast Period

Within North America, the United States is expected to dominate the market due to the increasing overuse of tobacco and an increasing number of government initiatives aimed at reducing substance abuse.

For instance, as per a December 2020 update by the Centers for Disease Control and Prevention (CDC), nearly 14 out of every 100 United States adults aged 18 years or older (14.0%) smoked cigarettes in 2019. As per the same source, an estimated 34.1 million adults in the United States currently smoke cigarettes, and more than 16 million Americans live with a smoking-related disease. Such a prevalent addiction population within the country will necessitate the demand for addiction treatments, in turn, driving the market growth in the United States.

Furthermore, various initiatives are being implemented by the United States government to monitor the symptoms and determine drug abuse among the American population. For instance, as per a February 2022 update, the United States government and the United Kingdom are administering Narcan, a brand name for the medicine naloxone, in 16 counties at no cost to help reduce overdose deaths. Such initiatives will further supplement the growth of substance abuse treatment within the country.

Additionally, the United States has an advanced healthcare system with one of the largest expenditures on healthcare. Its investment in research and development, along with measures to curb and eliminate substance abuse, is further aiding access to addiction treatments among Americans. As a result of these factors, a large population is able to get the required treatment it needs. For instance, as per a February 2022 update, Texas and some of its largest counties will receive USD 1.17 billion as an opioid relief fund as part of a nationwide settlement from three large pharmaceutical distribution companies. Moreover, in February 2022, the United States Department of Human Health and Services announced a USD 10 million Substance Abuse and Mental Health Services Administration (SAMHSA) grant program addressing the health needs of pregnant women and children affected by substance use. Such programs are anticipated to drive the demand for substance abuse treatment in the United States, thereby driving the market growth.

Thus, owing to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

Substance Abuse Treatment Market - Growth Rate by Region

Competitive Landscape

The substance abuse treatment market is competitive and consists of a fewer number of major players. Market leaders with more funds for research and a better distribution system have established their position in the market. The major players in the market are Alkermes, Mallinckrodt, GSK, Cipla, and Idiviour, among other market players.

Recent Developments

In June 2021, INDIVIOR PLC and AELIS FARMA announced a strategic partnership and option-license agreement to address the significant repercussions of cannabis use disorders (CUD), including cannabis-induced psychosis (CIP).

In May 2021, JB Chemicals & Pharmaceuticals Ltd (JBCPL) launched NOSMOK prescription medicated nicotine lozenges as part of a 360 Tobacco Cessation initiative on ‘World No Tobacco Day’ that will aid in reducing the urge to consume tobacco.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Drug Awareness Campaigns and Prevention Programs

      2. 4.2.2 High Number of Addicted Population

    3. 4.3 Market Restraints

      1. 4.3.1 Reluctance of Individuals for Accessing Treatment and Discontinuation of the Behavioral Therapies

      2. 4.3.2 Poor Treatment Compliance in Some Countries

    4. 4.4 Porter’s Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Treatment Type

      1. 5.1.1 Alcohol Addiction Treatment

      2. 5.1.2 Tobacco/Nicotine Addiction Treatment

      3. 5.1.3 Drug Abuse Treatment

      4. 5.1.4 Other Treatment Types

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Other Distribution Channels

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alkermes PLC

      2. 6.1.2 Abbvie Inc.

      3. 6.1.3 Cipla Ltd

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Mallinckrodt LLC

      6. 6.1.6 Indivior PLC

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Teva Pharmaceutical Industries Ltd

      10. 6.1.10 Orexo AB

      11. 6.1.11 Apotex

      12. 6.1.12 BioCorRx Inc.

      13. 6.1.13 Opiant Pharmaceuticals Inc.

      14. 6.1.14 Purdue Pharma LP

      15. 6.1.15 Novartis AG (Sandoz)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Substance Abuse Treatment Market market is studied from 2019 - 2027.

The Substance Abuse Treatment Market is growing at a CAGR of 7.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Mallinckrodt Pharmaceuticals, Cipla, GlaxoSmithKline PLC, Alkermes PLC, Indivior PLC are the major companies operating in Substance Abuse Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!